SELLAS Life Sciences (SLS) Common Equity (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Common Equity of $107.4 million for Q1 2026, up 286.94% year-over-year from $27.8 million in Q1 2025, and up 51.56% quarter-over-quarter from $70.9 million in Q4 2025.
SELLAS Life Sciences (SLS) Common Equity (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Common Equity for 17 consecutive years, with $107.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 286.94% year-over-year to $107.4 million; the TTM figure through Mar 2026 stood at $107.4 million (up 286.94% YoY), while the FY2025 annual figure was $70.9 million, up 648.77% from the prior year.
- Common Equity rose to $107.4 million in Q1 2026 per SLS's latest filing, from $70.9 million in the prior quarter.
- Across five years, Common Equity topped out at $107.4 million in Q1 2026 and bottomed at -$8.0 million in Q4 2023.
- Historically, Common Equity has averaged $21.3 million across 5 years, with a median of $12.6 million in 2022.
- Annual changes were most pronounced in 2023 — Common Equity tumbled 264.42% — and 2025, when it jumped 797.67%.
- SELLAS Life Sciences' Common Equity stood at $4.9 million in 2022, then sank by 264.42% to -$8.0 million in 2023, then jumped by 218.67% to $9.5 million in 2024, then soared by 648.77% to $70.9 million in 2025, then soared by 51.56% to $107.4 million in 2026.
- Business Quant data shows SLS's Common Equity at $107.4 million in Q1 2026, $70.9 million in Q4 2025, and $45.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 137.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.66 Mn |
| Mar 31, 2026 | 107.41 Mn |
| Dec 31, 2025 | 70.87 Mn |
| Sep 30, 2025 | 45.63 Mn |
| Jun 30, 2025 | 26.15 Mn |
| Mar 31, 2025 | 27.76 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 15.89 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Dec 31, 2023 | -7.98 Mn |
| Sep 30, 2023 | -3.83 Mn |
| Jun 30, 2023 | 4.84 Mn |
| Mar 31, 2023 | 13.17 Mn |
| Dec 31, 2022 | 4.85 Mn |
| Sep 30, 2022 | 12.60 Mn |
| Jun 30, 2022 | 19.06 Mn |
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 20.35 Mn |
| Sep 30, 2021 | 26.61 Mn |